Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation
Mark J. Levis(Sidney Kimmel Cancer Center), Jörge E. Cortes(Augusta University Health), Alan K. Burnett(Cardiff University), Björn Steffen(Goethe University Frankfurt), Alexander E. Perl(University of Pennsylvania), Denise Trone(Unknown), Philippe Rousselot(Université Paris-Saclay), Elihu H. Estey(University of Washington), Giovanni Martinelli(University of Bologna), Hartmut Döhner(University Hospital Ulm), Hervé Dombret(University of London Institute in Paris), Guy Gammon(Unknown), Eugen Leo(Urologische Klinik München)
Cited by 141
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k